ALK positive

P4, N=41, Active, not recruiting, Guangdong Association of Clinical Trials | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Jul 2025 --> Apr 2026

In this phase IV open-label study, patients with ALK-positive metastatic NSCLC that progressed on first-line alectinib or ceritinib received lorlatinib 100 mg once daily. Lorlatinib continued to show clinically meaningful benefit in patients with previously treated ALK-positive metastatic NSCLC. clinicaltrials.gov identifier is NCT04362072.

P1/2, N=56, Recruiting, Joshua Palmer | Trial completion date: Jun 2027 --> Feb 2029 | Trial primary completion date: Jun 2026 --> Feb 2028

P1, N=34, Not yet recruiting, Kyowa Kirin, Inc. | N=17 --> 34

P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting

P=N/A, N=240, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

After about 20 years of exciting improvements in treatment efficacy outcomes of advanced epidermal growth factor receptor (EGFR) mutant and anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC), also combined with a progressively better safety profile, from chemotherapy to new generation tyrosine kinase inhibitors (TKIs) (osimertinib, alectinib, brigatinib), the recent MARIPOSA and CROWN trials have changed this trend. The story would be easy and totally positive if these two innovative, amazing treatments were not associated with new peculiar features in safety profiles that must be discussed with patients, because they potentially affect their quality of life. When treating these patient populations, the peculiar safety profiles of amivantamab plu lazertinib and lorlatinib require a well-structured shared decision making, "where and when", both the high probability of a longer survival and the risk of worse quality of life must be well announced and explained to our patients before the shared final treatment choice.

P=N/A, N=9, Recruiting, Fudan University | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2026

Multidisciplinary collaboration is needed to determine the necessity and timing of intervention for pericardial effusions causing hemodynamic compromise in pregnancy. Sanguineous effusions should prompt evaluation for both aortic dissection and malignancy.

Small-molecule ALK inhibitors, including crizotinib, have demonstrated high overall response rates (67%-88%) and complete remission rates (~60%-80%) in relapsed or refractory ALK-positive ALCL, often with rapid clinical responses...In addition, it explores emerging strategies for integrating ALK inhibitors into precision-based management of T-cell lymphomas, including combination approaches with chemotherapy, immunotherapy or antibody-drug conjugates. Collectively, these developments highlight a paradigm shift towards biology-driven, personalized therapy in ALK-positive ALCL.